Fast-track push for rare cancer treatments
Luminaries are gathering in Sydney today to discuss how to accelerate access to innovative medicines for rare cancers in the outdated HTA processes, as relative five-year survival for rare cancers lags behind others.
To see the whole article, log in or create an account.